

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

June 2023

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font. Below it, the Māori name "TE PĀTAKA WHAIORANGA" is written in a smaller, uppercase, sans-serif font. The logo is centered within a white circle that overlaps a large, stylized graphic of white and grey wavy lines on a grey background.

PHARMAC  
TE PĀTAKA WHAIORANGA

# Contents

Summary of decisions effective 1 June 2023 .....	3
Section H changes to Part II .....	5
Index .....	10

## Summary of decisions

EFFECTIVE 1 JUNE 2023

- Amino acid formula (without phenylalanine) (PKU GMPro Ultra Lemonade) powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU GMPro Ultra Lemonade) powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet – to be delisted 1 December 2023
- Atenolol (Mylan Atenolol) tab 50 mg – PSS removed
- Atenolol (Viatris) tab 50 mg – addition of PSS
- Copper tab 2.5 mg, chelated – new listing
- Diatrizoate meglumine with sodium amidotrizoate (Gastrografin) oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle – price increase
- Diatrizoate meglumine with sodium amidotrizoate (Urografin) inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle – price increase
- Efavirenz with emtricitabine and tenofovir disoproxil (Mylan) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg – to be delisted 1 December 2023
- Emtricitabine with tenofovir disoproxil (Tenofovir Disoproxil Emtricitabine Viatris) tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – addition of PSS
- Emtricitabine with tenofovir disoproxil (Tenofovir Disoproxil Emtricitabine Mylan) tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – PSS removed
- Eptifibatide (Integrilin) inj 2 mg per ml, 10 ml vial and inj 750 mcg per ml, 100 ml vial – delisted 1 June 2023
- Exemestane (Pfizer Exemestane) tab 25 mg – price decrease and addition of PSS
- Iodixanol (Visipaque) inj 270 mg per ml (iodine equivalent), 50 ml bottle and 100 ml bottle – price increase
- Iodixanol (Visipaque) inj 320 mg per ml (iodine equivalent), 50 ml bottle, 100 ml bottle and 200 ml bottle – price increase
- Iohexol (Omnipaque) inj 240 mg per ml (iodine equivalent), 50 ml bottle – price increase
- Iohexol (Omnipaque) inj 300 mg per ml (iodine equivalent), 20 ml bottle, 50 ml bottle and 100 ml bottle – price increase

## Summary of decisions – effective 1 June 2023 (continued)

- Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 50 ml bottle, 75 ml bottle, 100 ml bottle, 200 ml bottle and inj 350 mg per ml, 500 ml bottle – price increase
- Lacosamide (Vimpat) tab 50 mg, 100 mg, 150 mg, 200 mg and inj 10 mg per ml, 20 ml vial – amended restriction criteria
- Meglumine iotroxate (Biliscopin) inj 105 mg per ml, 100 ml bottle – price increase
- Metformin hydrochloride (Metformin Viartis) tab immediate-release 850 mg – new listing
- Nicotine (Habitrol (Fruit)) and (Habitrol (Mint)) gum 2 mg, 384 pack – to be delisted 1 December 2023
- Nicotine (Habitrol (Fruit)) and (Habitrol (Mint)) gum 4 mg, 384 pack – to be delisted 1 December 2023
- Prednisolone sodium phosphate (Minims Prednisolone) eye drops 0.5%, single dose (preservative free) – price increase
- Sirolimus (Rapamune) tab 1 mg, 2mg and oral liq 1 mg per ml – amended restriction criteria
- Sodium fusidate [Fusidic acid] (Fucidin) tab 250 mg – price increase
- Solifenacin succinate (Solifenacin Mylan) tab 5 mg and 10 mg – PSS removed and to be delisted 1 December 2023
- Solifenacin succinate (Solifenacin Viartis) tab 5 mg and 10 mg – addition of PSS
- Stiripentol (Diacomit) cap 250 mg and powder for oral liq 250 mg sachet – amended restriction criteria
- Valganciclovir (Valganciclovir Viartis) tab 450 mg – new listing
- Vitamin B complex (Bplex) tab strong, BPC – price increase
- Zinc and castor oil (Boucher) oint, 500 g – to be delisted 1 November 2023
- Zinc and castor oil (Evara) oint, 500 g – new listing and addition of PSS
- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml, vial – PSS removed
- Zoledronic acid (Zoledronic acid Viartis) inj 4 mg per 5 ml, vial – addition of PSS

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

## Section H changes to Part II

Effective 1 June 2023

### ALIMENTARY TRACT AND METABOLISM

12	METFORMIN HYDROCHLORIDE (new listing) Tab immediate-release 850 mg.....	11.28	500	Metformin Viatris
22	COPPER (new listing) → Tab 2.5 mg, chelated			
27	VITAMIN B COMPLEX (↑ price) Tab strong, BPC .....	11.25	500	Bplex

### BLOOD AND BLOOD FORMING ORGANS

37	EPTIFIBATIDE (delisting) → Inj 2 mg per ml, 10 ml vial .....	138.75	1	Integrilin
	→ Inj 750 mcg per ml, 100 ml vial .....	405.00	1	Integrilin
Note: Integrilin inj 2 mg per ml, 10 vial and 750 mcg per ml, 100 ml vial to be delisted on 1 June 2023.				

### CARDIOVASCULAR SYSTEM

46	ATENOLOL (removal of PSS) Tab 50 mg – 5% DV Jan-22 to <b>31-5-23 2024</b> .....	9.33	500	Mylan Atenolol
46	ATENOLOL (PSS added) Tab 50 mg – <b>5% DV Jun-23 to 2024</b> .....	9.33	500	<b>Viatris</b>

### DERMATOLOGICALS

60	ZINC AND CASTOR OIL (new listing and addition of PSS) Oint – <b>5% DV Nov-23 to 2025</b> .....	4.25	500 g	<b>Evara</b>
Note: DV limit applies to the pack sizes of greater than 30 g. Note – Boucher oint 500 g to be delisted from 1 November 2023.				

### GENITO-URINARY SYSTEM

69	SOLIFENACIN SUCCINATE (addition of PSS) Tab 5 mg – <b>5% DV Jun-23 to 2024</b> .....	2.05	30	<b>Solifenacin Viatris</b>
	Tab 10 mg – <b>5% DV Jun-23 to 2024</b> .....	3.72	30	<b>Solifenacin Viatris</b>
69	SOLIFENACIN SUCCINATE (delisting and removal of PSS) Tab 5 mg – 5% DV Dec-21 to <b>31-5-23 2024</b> .....	2.05	30	Solifenacin Mylan
	Tab 10 mg – 5% DV Dec-21 to <b>31-5-23 2024</b> .....	3.72	30	Solifenacin Mylan
Note: Solifenacin Mylan tab 5 mg and 10 mg to be delisted from 1 December 2023.				

### HORMONE PREPARATIONS

70	ZOLEDRONIC ACID (removal of PSS) Inj 4 mg per 5 ml, vial – 5% DV Dec-21 to <b>31-5-23 2024</b> .....	18.00	1	Zoledronic acid Mylan
----	---	-------	---	-----------------------

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 June 2023 (continued)

70	ZOLEDRONIC ACID (PSS added) Inj 4 mg per 5 ml, vial – 5% DV Jun-23 to 2024 .....	18.00	1	Zoledronic acid Viatriis
----	---	-------	---	--------------------------

## INFECTIONS

86	SODIUM FUSIDATE [FUSIDIC ACID] († price) → Tab 250 mg.....	135.70	36	Fucidin
94	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (delisting) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) .....	106.88	30	Mylan
Note: Mylan tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) to be delisted from 1 December 2023				
97	VALGANCICLOVIR (new listing) → Tab 450 mg.....	132.00	60	Valganciclovir Viatriis
98	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (removal of PSS) → Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – 5% DV Dec-22 to 31-5-23 2024.....	15.45	30	Tenofovir Disoproxil Emtricitabine Mylan
98	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (PSS added) → Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – 5% DV Jun-23 to 2025 .....	15.45	30	Tenofovir Disoproxil Emtricitabine Viatriis

## NERVOUS SYSTEM

119	LACOSAMIDE (amended restriction criteria – new criteria shown only) → Tab 50 mg..... → Tab 100 mg..... → Tab 150 mg..... → Tab 200 mg..... → Inj 10 mg per ml, 20 ml vial	25.04 50.06 75.10 300.40 400.55	14 14 56 56 56	Vimpat Vimpat Vimpat Vimpat Vimpat
Restricted Initiation <i>Re-assessment required after 15 months</i> Both: 1 Patient has <del>partial-onset</del> <b>focal</b> epilepsy; and 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam, and any two of carbamazepine, lamotrigine, and phenytoin sodium (see Note) Note: <del>Patients-Those</del> <b>Those</b> of childbearing age <b>potential</b> are not required to <del>have a trial of</del> <b>phenytoin sodium</b> , sodium valproate, <b>or topiramate</b> .				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 June 2023 (continued)

121	STIRIPENTOL (amended Restriction criteria – new criteria shown only)			
	→ Cap 250 mg .....	509.29	60	Diacomit
	→ Powder for oral liq 250 mg sachet .....	509.29	60	Diacomit
	Restricted			
	Initiation			
	Paediatric neurologist			
	<i>Re-assessment required after 6 months</i>			
	Both:			
	1 Patient has confirmed diagnosis of Dravet syndrome; and			
	2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.			
	<b>Note: Those of childbearing potential are not required to have a trial of sodium valproate or topiramate.</b>			

134	NICOTINE (delisting)			
	Gum 2 mg .....	38.21	384	Habitrol (Fruit)
		38.21	384	Habitrol (Mint)
	Note: Habitrol (Fruit) and Habitrol (Mint) gum 2 mg, 384 pieces to be delisted from 1 December 2023			

134	NICOTINE (delisting)			
	Gum 4 mg .....	44.17	384	Habitrol (Fruit)
		44.17	384	Habitrol (Mint)
	Note: Habitrol (Fruit) and Habitrol (Mint) gum 4 mg, 384 pieces to be delisted from 1 December 2023			

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

156	EXEMESTANE (↓ price and addition of PSS)			
	Tab 25 mg – <b>5% DV Nov-23 to 2026</b> .....	9.86	30	<b>Pfizer Exemestane</b>

## SENSORY ORGANS

228	SIROLIMUS (amended restriction criteria – new criteria shown only)			
	→ Tab 1 mg.....	749.99	100	Rapamune
	→ Tab 2 mg.....	1,499.99	100	Rapamune
	→ Oral liq 1 mg per ml .....	449.99	60 ml	Rapamune
	Restricted			
	Initiation – refractory seizures associated with tuberous sclerosis complex*			
	Neurologist			
	<i>Re-assessment required after 6 months</i>			
	All of the following:			
	1 Patient has epilepsy with a background of documented tuberous sclerosis complex; and			
	2 Either:			
	2.1 Both:			
	2.1.1 Vigabatrin has been trialed and has not adequately controlled seizures; and			
	2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or			
	2.2 Both:			
	2.2.1 Vigabatrin is contraindicated; and			

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 June 2023 (continued)

continued...

- 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Patients ~~Those~~ of childbearing age **potential** are not required to ~~have a trial of~~ **phenytoin sodium**, sodium valproate, **or topiramate**.

242	PREDNISOLONE SODIUM PHOSPHATE († price) Eye drops 0.5%, single dose (preservative free) .....	41.20	20 dose	Minims Prednisolone
-----	--	-------	---------	---------------------

## VARIOUS

251	DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE († price) Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle .....	30.00	100 ml	Gastrografin
	Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle .....	90.00	1	Urografin
251	IODIXANOL († price) Inj 270 mg per ml (iodine equivalent), 50 ml bottle .....	260.00	10	Visipaque
	Inj 270 mg per ml (iodine equivalent), 100 ml bottle .....	480.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 50 ml bottle .....	260.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 100 ml bottle .....	480.00	10	Visipaque
	Inj 320 mg per ml (iodine equivalent), 200 ml bottle .....	950.00	10	Visipaque
251	IOHEXOL († price) Inj 240 mg per ml (iodine equivalent), 50 ml bottle .....	94.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 20 ml bottle .....	89.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 50 ml bottle .....	96.00	10	Omnipaque
	Inj 300 mg per ml (iodine equivalent), 100 ml bottle .....	166.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 50 ml bottle .....	98.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 75 ml bottle .....	130.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 100 ml bottle .....	170.00	10	Omnipaque
	Inj 350 mg per ml (iodine equivalent), 200 ml bottle .....	330.00	10	Omnipaque
	Inj 350 mg per ml, 500 ml bottle .....	515.00	6	Omnipaque
252	MEGLUMINE IOTROXATE († price) Inj 105 mg per ml, 100 ml bottle .....	159.00	100 ml	Biliscopin



	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

**Changes to Section H Part II – effective 1 June 2023 (continued)**

**SPECIAL FOODS**

261	<p>AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing)            → Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet... 936.00</p>	30	<b>PKU GMPPro Ultra Lemonade</b>
-----	--	----	--------------------------------------

Restricted

Initiation

All of the following:

- 1 Patient was previously receiving, or would receive PKU Sensation Berries under (RS1232); and
- 2 PKU Sensation Berries is unable to be sourced at this time; and
- 3 Patient has trailed the currently funded PKU Lophlex products and these were not tolerated.

Note: These criteria are attached to short term funding to cover an out-of-stock situation on PKU Sensation Berries supplied by Nutricia.

Note: PKU GMPPro Ultra Lemonade to be delisted from 1 December 2023

# Index

## Pharmaceuticals and brands

<b>A</b>			
Amino acid formula (without phenylalanine).....	9	Minims Prednisolone.....	8
Atenolol .....	5	Mylan Atenolol .....	5
<b>B</b>		<b>N</b>	
Biliscopin.....	8	Nicotine .....	7
Bplex .....	5	<b>O</b>	
<b>C</b>		Omnipaque .....	8
Copper.....	5	<b>P</b>	
<b>D</b>		Pfizer Exemestane.....	7
Diacomit .....	7	PKU GMPro Ultra Lemonade.....	9
Diatrizoate meglumine with sodium amidotrizoate...	8	Prednisolone sodium phosphate.....	8
<b>E</b>		<b>R</b>	
Efavirenz with emtricitabine and		Rapamune .....	7
tenofovir disoproxil.....	6	<b>S</b>	
Emtricitabine with tenofovir disoproxil.....	6	Sirolimus .....	7
Eptifibatide .....	5	Sodium fusidate [Fusidic acid] .....	6
Exemestane .....	7	Solifenacin succinate .....	5
<b>F</b>		Solifenacin Mylan.....	5
Fusidic acid.....	6	Solifenacin Viatriis.....	5
Fucidin.....	6	Stiripentol .....	7
<b>G</b>		<b>T</b>	
Gastrografin .....	8	Tenofovir Disoproxil Emtricitabine Mylan.....	6
<b>H</b>		Tenofovir Disoproxil Emtricitabine Viatriis .....	6
Habitrol (Fruit) .....	7	<b>U</b>	
Habitrol (Mint).....	7	Urografin.....	8
<b>I</b>		<b>V</b>	
Integrilin.....	5	Valganciclovir .....	6
Iodixanol .....	8	Valganciclovir Viatriis .....	6
Iohexol.....	8	Vimpat .....	6
<b>L</b>		Visipaque.....	8
Lacosamide .....	6	Vitamin B complex .....	5
<b>M</b>		<b>Z</b>	
Meglumine iotroxate.....	8	Zinc and castor oil.....	5
Metformin hydrochloride .....	5	Zoledronic acid .....	5, 6
Metformin Viatriis.....	5	Zoledronic acid Mylan .....	5
		Zoledronic acid Viatriis .....	6

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

